WebTURALIO is a prescription medicine used to treat certain adults who have tenosynovial giant cell tumor (TGCT) that is not likely to improve with surgery. TGCT is also known as giant cell tumor of the tendon sheath … WebTURALIO is a medication that blocks some of the inflammation signals that can cause TGCT tumors. TURALIO was studied in a clinical trial of 120 patients who had advanced TGCT, for whom surgery was not recommended. For 24 weeks, half of the patients in the trial were given TURALIO and half were given a placebo. * After 24 weeks, patients in …
HIGHLIGHTS OF PRESCRIBING INFORMATION
WebJun 23, 2024 · Pexidartinib (Monograph) Brand name: Turalio Drug class: Antineoplastic Agents - Kinase Inhibitors - Receptor Tyrosine Kinase Inhibitors - Tyrosine Kinase Inhibitors Chemical name: 5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine Molecular formula: C 20 H 15 ClF 3 N … Webx TURALIO can cause serious and potentially fatal liver injury. (5.1) x Monitor liver tests prior to initiation of TURALIO and at specified intervals during treatment. Withhold and dose reduce or permanently discontinue TURALIO based on severity of hepatotoxicity. (2. 2 , 5.1) x TURALIO is available only through a restricted program how to swear in hebrew
DailyMed - TURALIO- pexidartinib hydrochloride capsule
WebTURALIO acts as a CSF-1 regulator to target the tumor and interrupt cell signaling responsible for tumor growth and inflammation 1,6. Pexidartinib is a small-molecule tyrosine kinase inhibitor that targets colony-stimulating factor 1 receptor (CSF-1R), KIT proto-oncogene receptor. tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3 ... WebPexidartinib capsules (Turalio ®) is considered experimental, investigational or unproven for ANY other use. Background. Overview . Turalio, a kinase inhibitor, is indicated for the treatment of adults with . symptomatic tenosynovial giant cell tumor. associated with severe morbidity or functional limitations and not amenable to improvement ... WebJan 21, 2024 · The FDA approved TURALIO based on evidence from 1 clinical trial (NCT02371369) of 120 patients with Tenosynovial Giant Cell Tumor or TGCT. The trial was conducted in Australia, Canada, Europe, and ... reading studying